Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

Inclusion Criteria:

* Diagnosis of 1 of the following:

  * Cytologically or histologically proven unresectable solid tumor for which no curative treatment options exist (group I - dose-escalation phase)
  * Multiple myeloma or chronic lymphocytic leukemia requiring treatment (group II - maximum tolerated dose phase)

    * Failed ≥ 1 prior regimen
    * Non-secretory myeloma allowed
* No known standard therapy that is potentially curative or definitely capable of extending life expectancy exists
* Tumor amenable to serial sampling (group II)
* ECOG performance status 0-2
* Absolute neutrophil count ≥ 1,500/mm\^3
* Hemoglobin ≥ 9 g/dL
* Platelet count ≥ 100,000/mm\^3 (75,000/mm\^3 for patients with multiple myeloma \[group II\])
* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST ≤ 3 times ULN (5 times ULN if liver involvement)
* Creatinine ≤ 1.5 times ULN (2.5 times ULN for patients with multiple myeloma \[group II\])
* Life expectancy ≥ 12 weeks
* No uncontrolled infection
* No New York Heart Association class III or IV heart disease
* No uncontrolled hypertension, labile hypertension, or history of poor compliance with antihypertensive medication
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No sensory peripheral neuropathy of any etiology \> grade 1 or neuropathic pain of any etiology
* No active HIV infection requiring therapy
* No inability to swallow that would preclude use of oral medications
* No evidence of bleeding diathesis
* Medically capable and willing to provide biologic specimens as required (mandatory for patients in group II)
* Priorbortezomib allowed
* More than 3 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas) and recovered
* More than 4 weeks since prior immunotherapy or biologic therapy
* More than 2 weeks since prior steroid therapy (group II only)
* No prior anti-vascular endothelial growth factor therapy
* More than 4 weeks since prior full-field radiotherapy (2 weeks for limited-field radiotherapy)
* No prior radiation to \> 25% of bone marrow
* More than 4 weeks since major surgery (e.g., laparotomy) (2 weeks for minor surgery)

  * Insertion of a vascular access device is not considered major or minor surgery
* No concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary other therapy considered investigational
* No concurrent prophylactic colony-stimulating factors
* No concurrent therapeutic anticoagulation

  * Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) of venous or arterial access devices allowed provided requirements for PT, INR, or PTT are met
* No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, and phenobarbital), rifampin, or Hypericum perforatum (St. John's Wort)
* No concurrent participation in any other study involving a pharmacologic agent (e.g., drugs, biologics, immunotherapy, or gene therapy), either for symptom control, or therapeutic intent